Antigen-Specific Adaptive Immune Responses in Fingolimod-Treated Multiple Sclerosis Patients

Department of Neurology, Clinical Neuroimmunology Laboratory, University Hospital Basel, Switzerland.
Annals of Neurology (Impact Factor: 11.91). 02/2011; 69(2):408-13. DOI: 10.1002/ana.22352
Source: PubMed

ABSTRACT T cells exit secondary lymphoid organs along a sphingosine1-phosphate (S1P) gradient and, accordingly, are reduced in blood upon fingolimod-mediated S1P-receptor (S1PR)-blockade. Serving as a model of adaptive immunity, we characterized cellular and humoral immune responses to influenza vaccine in fingolimod-treated patients with multiple sclerosis (MS) and in untreated healthy controls. Although the mode of action of fingolimod might predict reduced immunity, vaccine-triggered T cells accumulated normally in blood despite efficient S1PR-blockade. Concentrations of anti-influenza A/B immunoglobulin (Ig)M and IgG also increased similarly in both groups. These results indicate that fingolimod-treated individuals can mount vaccine-specific adaptive immune responses comparable to healthy controls.